Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022

Rhea-AI Summary

Cyteir Therapeutics, Inc. (NASDAQ: CYT) will host a conference call on March 16, 2022, at 4:30 p.m. ET, to discuss its fourth quarter and full year 2022 financial and operational results. Interested parties can access the live audio webcast on the company's website and the archived version will be available for 30 days. Cyteir is focused on developing next-generation synthetically lethal therapies for cancer, with its lead compound, CYT-0851, targeting DNA repair mechanisms in cancer cells.

Positive

• Upcoming conference call to detail fourth quarter and full year 2022 results may provide insights into financial performance.
• Lead compound CYT-0851 targets key cancer vulnerabilities, potentially leading to significant therapeutic advancements.

Negative

• None.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss fourth quarter and full year 2022 financial and operational results.

The live audio webcast can be accessed via the Investor Relations section of the Company’s website at www.cyteir.com. The archived webcast will remain available for replay on Cyteir’s website for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005905/en/

INVESTORS:

Lisa Hayes

Vice President, Investor Relations and Corporate Communications

908-868-8926

Lisa.Hayes@cyteir.com

MEDIA:

Michele Parisi

925-429-1850

mparisi@forwardhealthinc.com

Source: Cyteir Therapeutics

FAQ

When will Cyteir Therapeutics discuss its 2022 financial results?

Cyteir Therapeutics will host a conference call on March 16, 2022, at 4:30 p.m. ET.

What is the lead compound of Cyteir Therapeutics?

The lead compound of Cyteir Therapeutics is CYT-0851, designed to inhibit RAD51-mediated DNA repair.

Where can I access the Cyteir Therapeutics conference call?

The conference call can be accessed via the Investor Relations section on Cyteir's website.

Will the conference call be available for replay?

Yes, the archive of the conference call will be available for replay on Cyteir's website for 30 days.